Neurologically impaired children account for almost half of the fundoplication procedures performed for gastroesophageal reflux disease. Aim of the present study was to report results of antireflux surgery in neurologically impaired children. A retrospective study of neurologically impaired children who underwent fundoplication over a 13-year period (1999–2012) was performed. Recurrence rate, major complications and parents/caregivers perceptions of their child's quality of life following antireflux surgery were analyzed. A total of 122 children (median age: 8 years 9 months; range: 3 months to 18 years) had open “tension-free” Nissen fundoplication, gastrostomy + /− pyloroplasty. Gastroesophageal reflux disease was in all cases documented by at least two diagnostic exams. Median duration of follow-up was 9.7 (1.9–13) years. Three (2.4%) recurrences were documented and required surgery re-do. Major complications were 6%. Seventy-nine of 87 (90%) caregivers reported that weight gain was improved after fundoplication with a median score of 1 (IQR: 1–2). Significant improvement was perceived in postoperative overall quality of life. In this series of fundoplication recurrence incidence was low, serious complications were uncommon and caregivers’ satisfaction with surgery was high. Accurate patient’s selection and creating a “low-pressure” surgical system are mandatory to obtain these results.
31 October 2013 in Pediatric Surgery International
Objective: To evaluate the long-term effectiveness of laparoscopic sleeve gastrectomy (LSG) in pediatric and transition age patients with Prader–Willi syndrome (PWS). Design: Single-center, longitudinal, retrospective cohort study. Methods: We reviewed the electronic health records of 110 patients with PWS and 268 subjects undergoing LSG. We included 16 patients with PWS and severe obesity (PWS-LSG) and 32 matched non-syndromic patients with obesity (OB-LSG), both undergoing LSG, and 16 patients with PWS receiving lifestyle intervention only (PWS-LS). The primary endpoint was ΔBMI-SDS% at 5 years. Results: In PWS-LSG, BMI-SDS decreased from 5.18 to an early nadir at 1-2 years (median ΔBMI-SDS% ∼−26%), then partially rebounded to 4.75 at 5 years, with ΔBMI-SDS% −16.9% (P = .012). Conventional metrics confirmed this attenuated response, with %BMI change −2.8% and absolute ΔBMI-SDS −1.10 at 5 years. In OB-LSG, BMI-SDS declined from 4.95 to 2.24, with larger and more sustained improvement (ΔBMI-SDS% −57.4%; P < .001 within-group; P = .002 vs PWS-LSG), corresponding to a %BMI change −40.1% and absolute ΔBMI-SDS −2.81 at 5 years. In PWS-LS, BMI-SDS increased from 2.25 to 3.19 (ΔBMI-SDS% + 36.4%, P = .003). The mean number of obesity-related comorbidities decreased in PWS-LSG (2.69 ± 1.66 to 1.94 ± 1.18; P = .041) and in OB-LSG (1.25 ± 0.88 to 0.56 ± 0.76; P < .001), but increased in PWS-LS (1.56 ± 0.96 to 2.44 ± 1.32; P = .004). Conclusion: In PWS, LSG produces clinically relevant early weight loss with partial maintenance at 5 years, but markedly attenuated long-term benefit compared with non-syndromic peers. Nevertheless, when interpreted against the progressive worsening of obesity and cardiometabolic comorbidities observed with lifestyle intervention alone, LSG appears to modify disease trajectory in PWS.